Research programme: cytokine therapeutics - Boehringer Ingelheim/Trutino Biosciences
Latest Information Update: 28 Mar 2024
At a glance
- Originator Trutino Biosciences
- Class Antineoplastics; Cytokines; Immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer